- Motley Fool•yesterday
A clinical trial for the biotech's lead drug matters more than earnings.
- Investopedia•3 days ago
ImmunoGen failed to meet analysts' revenue and earnings estimates for the fourth quarter.
- Zacks•3 days ago
ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.
IMGN : Summary for ImmunoGen, Inc. - Yahoo Finance
ImmunoGen, Inc. (IMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||2.60 x 3200|
|Ask||2.61 x 4400|
|Day's Range||2.43 - 2.65|
|52 Week Range||1.51 - 9.78|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.46|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|